Crossject secures 6.7 million euros in funding for the development of three new drugs
Friday, November 06, 2015
Crossject secures 6.7 million euros ($7.3 million) in funding for the development of three new drugs.
Announces that it has been awarded by Bpifrance a refundable grant of 6.7 million euros, over three years, as part of industrial projects of future (projets industriels d'avenir or PIAVE) scheme.
reuters.com
